Free Trial

Paula Green Sells 918 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience logo with Medical background
Remove Ads

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 918 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the sale, the senior vice president now owns 130,912 shares of the company's stock, valued at $5,355,609.92. The trade was a 0.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Paula Green also recently made the following trade(s):

  • On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65.
  • On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $7,294.40.
  • On Friday, December 20th, Paula Green sold 282 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total transaction of $12,661.80.

Twist Bioscience Stock Up 1.7 %

TWST stock traded up $0.65 during mid-day trading on Friday, hitting $39.77. 396,260 shares of the company were exchanged, compared to its average volume of 992,561. The company has a market capitalization of $2.37 billion, a PE ratio of -11.77 and a beta of 2.15. The firm has a fifty day simple moving average of $45.91 and a 200 day simple moving average of $45.31. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same quarter last year, the business posted ($0.75) EPS. Twist Bioscience's quarterly revenue was up 24.1% compared to the same quarter last year. On average, research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TWST has been the topic of a number of recent research reports. Robert W. Baird boosted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. TD Cowen reissued a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Wolfe Research started coverage on shares of Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and an average target price of $54.40.

Get Our Latest Stock Analysis on Twist Bioscience

Institutional Trading of Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC bought a new position in shares of Twist Bioscience in the 4th quarter worth about $56,984,000. Thrivent Financial for Lutherans bought a new position in Twist Bioscience in the third quarter worth about $43,992,000. Marshall Wace LLP boosted its stake in Twist Bioscience by 15,927.8% in the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after acquiring an additional 840,828 shares during the period. State Street Corp grew its holdings in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock valued at $36,042,000 after purchasing an additional 521,272 shares during the last quarter.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Stories

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Should You Invest $1,000 in Twist Bioscience Right Now?

Before you consider Twist Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.

While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads